Onclive Team

Articles

City of Hope Awarded $7.5 Million to Develop Better Treatment for Rare, Incurable Cancer

April 18th 2019

City of Hope recently received $7.5 million in grant awards to study a rare type of blood cancer that affects the skin: cutaneous T cell lymphoma.

Birrer Shares Perspective on Folate Receptor Alpha-Targeting Agents in Ovarian Cancer

April 18th 2019

Michael Birrer, MD, PhD, discusses the evolution of folate receptor alpha-targeting agents in ovarian cancer.

Evaluating the Role of Folate Receptor Alpha Expression in Ovarian Cancer

April 17th 2019

Multiple agents that target folate receptor alpha have been developed and are currently under investigation for the treatment of patients with ovarian cancer.

Baylor Scott & White Health Names New Chief of Oncology for North Texas

April 12th 2019

Baylor Scott & White Health named Ronan Kelly, MBBCh, MD, MBA, chief of oncology for the organization's North Texas medical centers.

Updated Data Continue to Showcase Efficacy of Larotrectinib, Entrectinib in NSCLC

April 11th 2019

Larotrectinib showcased an overall response rate of 71% in patients with non–small cell lung cancer harboring NTRK gene fusions.

Highlighting Breakthroughs in Breast Cancer in Nashville

April 10th 2019

We traveled to Nashville, Tennessee, for a State of the Science Summit™ on Breast Cancer, which focused on some of the practice-changing updates that have been occurring in the field.

Breast Cancer Leaders Reflect on Progress

April 5th 2019

This year we are celebrating the 20th anniversary of our flagship publication OncologyLive. To mark the occasion, we are asking oncology leaders to reflect on the tremendous progress made in cancer research and practice over the past 2 decades.

Spotlight on Clinical Scenarios in GEJ Cancer

April 3rd 2019

In keeping up with the rapidly changing landscape of gastroesophageal junction cancer, we sat down with Joseph Chao, MD, to discuss a clinical scenario he faced in practice, and how he used the latest data available to inform his treatment for his patient.

LOXO-195 Active After Initial Anti-TRK Failure in Multiple Tumor Types

April 2nd 2019

A third of patients with advanced TRK fusion tumors had objective responses to the second-generation TRK inhibitor LOXO-195 after failure of initial anti-TRK therapy.

Data Support TMB as Marker for Durvalumab Activity in NSCLC

April 2nd 2019

Tumor mutational burden identified patients who obtained a survival benefit with the PD-L1 inhibitor durvalumab, as initial therapy versus chemotherapy for advanced non–small cell lung cancer, even though the primary analysis of the randomized trial showed no difference between treatment groups, according to a new analysis.

T-VEC Plus Chemo Hits High pCR Rate in TNBC

April 1st 2019

A majority of patients with large triple-negative breast tumors achieved pathologic complete response when treated with the viral oncolytic talimogene laherparepvec plus neoadjuvant chemotherapy.

CAR T Cells Targeting Mesothelin Show Strong Early Signal in Advanced Solid Cancers

April 1st 2019

CAR T cells targeting mesothelin-expressing tumors demonstrated safety and efficacy in a preliminary clinical evaluation in patients with malignant pleural disease.

Gaining Insight Into Progress Made With Genitourinary Cancers in Pasadena

March 28th 2019

We traveled to Pasadena, California, for a State of the Science Summit™ on Genitourinary Malignancies, which focused on the rapidly evolving landscapes of kidney, bladder, and prostate cancer.

Ali McBride, PharmD, MS, BCOP, Becomes ACCC President 2019-2020

March 27th 2019

Ali McBride, PharmD, MS, BCOP, was named 2019-2020 President of the Association of Community Cancer Centers during its 45th Annual Meeting and Cancer Center Business Summit on March 22, 2019, in Washington, D.C.

Navigating New Advances in Breast Cancer in NYC

March 20th 2019

We traveled to NewYork City, New York, for a State of the Science Summit™ on Breast Cancer, which focused on the latest updates in the rapidly evolving paradigms of triple-negative breast cancer, HER2-positive breast cancer, hormone receptor-positive, HER2-negative disease, and more.

Spotlight on Clinical Scenarios in Rectal Adenocarcinoma

March 16th 2019

We sat down with Marwan Fakih, MD, a professor in the Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations at the Comprehensive Cancer Center, to discuss a clinical scenario he faced in practice, and how he used the latest data available to inform his treatment for his patient.

Perlmutter Earns NCI Comprehensive Cancer Center Designation

March 15th 2019

The National Cancer Institute (NCI) has designated NYU Langone Health’s Laura and Isaac Perlmutter Cancer Center as a Comprehensive Cancer Center, the highest rank awarded by the NCI. Perlmutter joins an elite group of 50 cancer centers across the country that have earned this distinction.

Observing the Latest Advances in Ovarian Cancer in Boston

March 7th 2019

We traveled to Boston, Massachusetts, for a State of the Science Summit™ on Ovarian Cancer and Soft Tissue Sarcoma, which focused on the facets of genetic testing in ovarian cancer, surgical options available for patients with newly diagnosed disease, and emerging strategies for the treatment of patients with uterine sarcomas, among other key topics.

Panel Proposes Standards for Reporting Data From Immuno-Oncology Trials

March 6th 2019

The standards for reporting findings from immunotherapy studies should reflect the unique efficacy and toxicity characteristics of this rapidily emerging modality, with detailed and transparent explanations of definitions.

Learning More About Lung Cancer in Kansas City

February 27th 2019

We traveled to Kansas City, Missouri, for a State of the Science Summit™ on Advanced Non–Small Cell Lung Cancer, which focused on recent progress made in squamous NSCLC and small cell lung cancer, provided tips on how to navigate the complex paradigm of oncogene-driven disease, and shed light on emerging biomarkers in the space.